As Europe learns to live with the pandemic, the development and swift global deployment of safe and effective vaccines against COVID-19 remains an essential element in the eventual solution to the public health crisis. [ Ссылка ] #eudebates #NextGenerationEU #MFF #EUbudget #Covid_19 #coronavirus #CoronavirusOutbreak #Corona #COVD19 #Health
In this context, the Commission is working to ensure that there will be access to safe vaccines across Europe, and encourages a coordinated approach of vaccination strategies for deployment of the vaccines. Today, ahead of the discussion of EU Leaders, the Commission is presenting the key elements to be taken into consideration by Member States for their COVID-19 vaccination strategies in order to prepare the European Union and its citizens for when a safe and effective vaccine is available, as well as priority groups to consider for vaccination first.
President of the European Commission, Ursula von der Leyen, said: “A safe and effective vaccine is our best shot at beating coronavirus and returning to our normal lives. We have been working hard to make agreements with pharmaceutical companies and secure future doses. Now, we must ensure that once a vaccine is found, we are fully prepared to deploy it. With our Vaccination Strategy, we are helping EU countries prepare their vaccination campaigns: who should be vaccinated first, how to have a fair distribution and how to protect the most vulnerable. If we want our vaccination to be successful, we need to prepare now.”
Stella Kyriakides, Commissioner for Health and Food Safety, said: “It is with great concern that I am witnessing the increasingly rapid rise of infection rates all across the EU. Time is running out – everyone’s first priority should be to do what it takes to avoid the devastating consequences of generalised lockdowns. And we must all prepare for the next steps. The vaccine will not be a silver bullet, but it will play a central role to save lives and contain the pandemic. And when and if a safe and efficient vaccine is found, we need to be prepared to roll it out as quickly as possible, including building citizens’ trust in its safety and efficacy. Vaccines will not save lives – vaccinations will.”
As Europe moves to the next stage of the COVID-19 pandemic, it is even more imperative that countries follow common vaccination strategies and approaches. At the Special European Council meeting of 2 October, Member States called on the Council and Commission to further step up the overall coordination effort and the work on the development and distribution of vaccines at EU level[2].
On 24 September, the European Centre for Disease Prevention and Control (ECDC) published its updated risk assessment regarding the COVID-19 pandemic, alongside a set of guidelines for non-pharmaceutical interventions (such as hand hygiene, physical distancing, cleaning and ventilation).
As stressed by President von der Leyen in the State of the Union 2020 Address, Europe needs to continue to handle the COVID-19 pandemic with extreme care, responsibility and unity, and use the lessons learnt to strengthen the EU’s crisis preparedness and management of cross-border health threats.
On 15 July, the Commission adopted a Communication on short-term EU health preparedness, calling on Member States to have prevention, preparedness and response measures ready in case of future COVID-19 outbreaks. The Communication made a set of recommendations to achieve this, in the areas of e.g. testing, contact tracing and health system capacities. The effective implementation of these measures requires coordination and effective information exchange between Member States. The recommendations provided in the Strategy are still relevant and Member States are encouraged to follow them.
One of the main action points necessary for Europe to overcome the coronavirus pandemic is accelerating the development, manufacturing, and deployment of vaccines against COVID-19. The EU’s vaccines strategy published in June charts the way forward.
Vaccine safety, quality and efficacy are the cornerstones of any vaccine development and authorisation process, and vaccine developers are required to submit extensive documentation and data to the European Medicines Agency through the EU Marketing Authorisation procedure. After authorisation, EU law requires that the safety of the vaccine as well as its effectiveness be monitored. Further evidence will need to be centrally collected to assess the impact and effectiveness of COVID-19 vaccines once rolled out in the population from a public health perspective. This will be key to overcoming the pandemic and instilling confidence in Europeans.
[ Ссылка ] #eudebates
